publication . Article . 2021 . Embargo end date: 14 Feb 2022

Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial:Protocol and statistical analysis plan

Warrer Munch, Marie; Granholm, Anders; Nainan Myatra, Sheila; Kumar Tirupakuzhi Vijayaraghavan, Bharath; Cronhjort, Maria; Rubenson Wahlin, Rebecka; Jakob, Stephan M.; Cioccari, Luca; Nørregaard Kjær, Maj Brit; Kingo Vesterlund, Gitte; ...
Embargo English
  • Published: 01 Jul 2021
  • Country: Denmark
<p>Background: The coronavirus disease 2019 (COVID-19) pandemic has resulted in millions of deaths and overburdened healthcare systems worldwide. Systemic low-dose corticosteroids have proven clinical benefit in patients with severe COVID-19. Higher doses of corticosteroids are used in other inflammatory lung diseases and may offer additional clinical benefits in COVID-19. At present, the balance between benefits and harms of higher vs. lower doses of corticosteroids for patients with COVID-19 is unclear. Methods: The COVID STEROID 2 trial is an investigator-initiated, international, parallel-grouped, blinded, centrally randomised and stratified clinical trial a...
Related Organizations
Any information missing or wrong?Report an Issue